Clinical Trials in Sweden

• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 Phase III Acute lymphoblastic leukemia Princess Maxima Center For Pediatric Oncology
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting
  2023-506548-18-00 Phase II/III Dermatitis atopic Sanofi-Aventis Recherche & Developpement
• This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against co… Recruiting
  2022-502030-12-01 Phase I Treatment of patients with Hemophilia A who have developed i… Cell4Cure AB
• An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting
  2023-505766-28-00 Phase II/III Hereditary angioedema Pharvaris Netherlands B.V.
• A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign… Recruiting
  2022-501374-19-00 Phase II Aggressive and Indolent B-cell Malignancies (mantle cell lym… Merck Sharp & Dohme LLC
• The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR… Recruiting
  2024-512119-34-00 Phase II MSI-H/dMMR metastatic colorectal cancer Pfizer Inc.
• BIVV020 (SAR445088) in prevention and treatment of antibody-mediated rejection (AMR) Recruiting
  2023-509936-25-00 Phase II Transplant Rejection Sanofi-Aventis Recherche & Developpement
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 Phase III Adenocarcinoma of the prostate Unicancer
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting
  2023-505749-14-00 Phase III c-Met overexpressing EGFR wildtype non-squamous non-small ce… AbbVie Deutschland GmbH & Co. KG
• OPEN LABEL, MAINTENANCE STUDY OF ORAL TOFACITINIB IN CHILDREN WITH MODERATE TO SEVERE ULCERATIVE COLITIS Recruiting
  2023-509694-22-00 Phase III Ulcerative Colitis (UC) Pfizer Inc.
• A Phase 2 Study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia os… Recruiting
  2024-511469-13-00 Phase II Fibrodysplasia Ossificans Progressiva Clementia Pharmaceuticals Inc. An Ipsen Company
• A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting
  2023-509138-21-00 Phase III Pulmonary Arterial Hypertension (PAH) Acceleron Pharma Inc.
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l… Recruiting
  2024-511267-28-00 Phase III B-cell malignancies BeOne Medicines AG
• TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A Prospective, randomised-controlled, double-dummy, double-blind phase 3 … Recruiting
  2024-517606-29-00 Phase III Central retinal artery occlusion Oslo University Hospital HF
• A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl… Recruiting
  2022-501687-18-00 Phase II Advanced malignancies and IAI diseases Incyte Corp.
• Stem cell transplantation in diffuse cutaneous systemic sclerosis: upfront therapy or rescue therapy after failure of immunosuppressants Recruiting
  2023-505877-34-00 Phase IV Diffuse cutaneous systemic sclerosis according to the ACR/EU… University Medical Center Utrecht
• NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The… Recruiting
  2022-500966-82-00 Phase III Resectable locally advanced squamous cell carcinoma (SCC) of… Karolinska University Hospital
• Evaluation of the Pharmacokinetics and Safety of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis … Recruiting
  2023-505060-11-00 Phase I (Other) Polyarticular Course Juvenile Idiopathic Arthritis AbbVie Deutschland GmbH & Co. KG
• Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy. (SOLSTICE… Recruiting
  2024-516180-85-00 Phase III Metastatic colorectal cancer Institut De Recherches Internationales Servier IRIS
• Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting
  2023-504694-20-00 Phase I/II pediatric CD22-positive relapsed/refractory Acute Lymphoblas… Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting
  2024-512358-78-00 Phase I (FiH) Solid Tumors Partner Therapeutics Inc.
• CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids. Recruiting
  2025-520571-66-00 Phase III Prostate cancer Region Vaesterbotten
• The Efficacy of Pressurised Intraperitoneal aerosol chemotherapy (PIPAC) combined with CURativE intent minimally invasive radical resection … Recruiting
  2024-516194-76-00 Phase II Gastric adenocarcinoma Odense University Hospital
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 Phase III/IV Moderate to Severe Plaque Psoriasis Bristol-Myers Squibb Services Unlimited Company

Showing 217–240 of 1,115 trials